Semper Paratus shareholders approve business combination with Tevogen

Semper Paratus Acquisition Corporation (LGST) announced that its shareholders have approved the proposed business combination with Tevogen Bio Inc, a Delaware corporation, at an extraordinary general meeting of Semper Paratus’ shareholders that was held on Wednesday, January 31, 2024. Each of the proposals presented at the Meeting was approved, and the Business Combination is expected to be consummated as soon as practicable following the satisfaction or waiver of the remaining closing conditions described in Semper Paratus’ definitive proxy statement, which was filed with the U.S. Securities and Exchange Commission on January 10, 2024, as supplemented by a Supplement No. 1 filed on January 24, 2024 and Supplement No. 1 filed on January 24, 2024, including the condition that the common stock of the combined company will have been approved for listing on a tier of The Nasdaq Stock Market. Following the closing of the Business Combination, common stock of the combined company is expected to begin trading on Nasdaq under the symbol “TVGN”.